Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01538563
Recruitment Status : Completed
First Posted : February 24, 2012
Last Update Posted : June 23, 2017
Information provided by (Responsible Party):
Onconova Therapeutics, Inc.

Brief Summary:
The primary purpose of this study is to determine the highest dose of ON 01910.Na that can be safely given as an intravenous infusion over 24 hours once a week in a 3-week cycle to patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumors Advanced Cancer Cancer Neoplasms Drug: rigosertib sodium Phase 1

Detailed Description:
This is an open-label, dose-escalating Phase I study of ON 01910.Na in patients with advanced cancers, who have satisfied the inclusion/exclusion criteria enumerated in this protocol. Patients will receive ON 01910.Na intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. Safety monitoring will be done for at least 3 weeks before escalation to the next dose level. As of Amendment 7, up to 6 patients with gynecological malignancies will be enrolled at the 2400 mg/m2 dose level to determine the appropriateness of this dose as the Recommended Phase Two Dose (RPTD).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Dose Escalation Study of ON 01910.Na by 24 Hour Continuous Infusion Per Week in Patients With Advanced Cancer
Study Start Date : June 2006
Actual Primary Completion Date : July 2010
Actual Study Completion Date : November 2011

Intervention Details:
  • Drug: rigosertib sodium
    Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
    Other Names:
    • ON 01910.Na Concentrate
    • ON 01910.Na
    • rigosertib

Primary Outcome Measures :
  1. Number of dose limiting toxicities (DLTs) [ Time Frame: 21 days after first administration of ON 01910.Na ]

    DLTs are defined as:

    • Grade 3 non-hematological toxicity other than nausea, vomiting, diarrhea, fever, stomatitis, esophagitis/dysphagia.
    • Recurrent grade 3 toxicity uncontrolled by optimal therapy or Grade 4 nausea, vomiting, diarrhea and fever.
    • Grade 3 stomatitis and/or esophagitis/dysphagia for > 5 days.
    • Grade 4 neutropenia or thrombocytopenia for > 5 days measured at least 2X 2-3 days apart.
    • Neutropenic fever, as defined in Protocol.
    • Failure to recover neutrophils (> 1,500 per microliter) or platelets (>75,000 per microliter) before the next weekly dose.

Secondary Outcome Measures :
  1. Number of Adverse Events (AEs) [ Time Frame: 30 days after last infusion of study drug ]
    All AEs (except Grade 1 and 2 laboratories abnormalities that do not require an intervention) are recorded in Case Report Forms and source documentation.

  2. Severity of Adverse Events (AEs) [ Time Frame: 30 days after last infusion of study drug ]
    Severity of AEs are determined according to Common Terminology Criteria for Adverse Events (Version 3.0)

  3. Relationship of Adverse Events (AEs) to Study Treatment [ Time Frame: 30 days after last infusion of study drug ]
    Relationship assessed as Not related, Unlikely, Possibly, Probably, or, Definitely according to Guidance in Appendix II of Protocol.

  4. Concentration of ON 01910.Na in plasma versus time [ Time Frame: Up to 48 hours after infusion of study drug during Week 1 in Cycles 1 and 2 ]
    Blood samples will be collected at following time points: Pre-dose; 1 h after start of infusion; 3 h; 6 h; 12 h; 18 h; 24 h; 10 min after end of infusion; 20 min; 30 min; 1 h; 2 h; 4 h; 8 h; 24 h; and, 48 h. Plasma will be prepared from these samples. Concentration of ON 01910.Na will be determined by validated method.

  5. Change in size of target lesions recorded at baseline [ Time Frame: 30 days after last infusion of study drug ]
    The same method of assessment for each identified and recorded lesion will be used at baseline and each follow-up.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have histologically confirmed solid tumor (leukemias and lymphomas excluded) malignancy that is incurable and for which standard (FDA approved or established standard clinical practice), curative, or palliative measures do not exist or are no longer effective.
  • Patients with disease amenable to sequential biopsies will be requested to undergo two tumor biopsies and two normal skin biopsies, but patients may decline and still be eligible for enrollment during this escalation stage.
  • At least 3 weeks since the last dose of other potentially myelosuppressive treatment (at least 6 weeks since last dose of nitrosoureas or mitomycin C) and recovery from manifestations of reversible drug toxicity (alopecia, stable residual neuropathy, and residual hand and foot syndrome are excluded). Patients with prior doxorubicin chemotherapy must have total cumulative dose of no more than 450 mg/m2.
  • Patients with prior radiotherapy are eligible provided a minimum of 4 weeks have passed and the maximal area of hematopoietic active bone marrow treated was less than 25%.
  • ECOG performance status ≤2.
  • Patients must have nearly normal organ and marrow function as defined below:
  • Hgb > 9 gm/dl (must not require transfusional support but erythropoietin therapy is permitted)
  • WBC > 4,000 per microliter
  • Absolute neutrophil count > 1,500 per microliter
  • Platelets ≥ 100,000 per microliter
  • Total bilirubin within 1.5 times institutional upper normal limit
  • AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper normal limit. (If liver function abnormalities are due to metastatic disease, patients are eligible provided the transaminases are < 5 times institutional upper normal limit. Patients with primary liver disease with these parameters will be ineligible.)
  • Serum creatinine within normal institutional limits or estimated creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
  • Women of child-bearing potential and men must agree to use adequate contraception prior to study entry.
  • Ability to understand and the willingness to sign a written informed consent document.
  • All ethnic groups are eligible for this trial.

Inclusion Criteria - Dose Confirmation Phase Same inclusion criteria as in the Dose Escalation phase described above, except Patients must have an ECOG performance of 0 or 1.

Exclusion Criteria:

  • Recent major surgery (within the past 14 days), chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy within 4 weeks prior to entering the study, or those who have not recovered from adverse events (except alopecia, stable residual neuropathy, and residual hand and foot syndrome) due to previously administered agents.
  • Patients may not be on any other investigational agents or concurrent chemotherapy, radiotherapy, hormonal treatments, bone marrow transplantation, or immunotherapy. Patients who have previously had a Bone Marrow Transplant are excluded from this study.
  • Known brain metastases, except brain metastases that have been previously removed or irradiated and currently have no clinical impact.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ON 01910.Na.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, bleeding, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant and nursing women are excluded.
  • HIV-positive patients receiving combination anti-retroviral therapy are excluded.
  • Ascites requiring active medical management including paracentesis, peripheral bilateral edema, hyponatremia (serum sodium value less than 134 Meq/L).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01538563

United States, New York
Albert Einstein Cancer Center
The Bronx, New York, United States, 10461
Sponsors and Collaborators
Onconova Therapeutics, Inc.
Principal Investigator: Sridhar Mani, MD Albert Einstein College of Medicine, Inc.

Publications of Results:
Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.

Responsible Party: Onconova Therapeutics, Inc. Identifier: NCT01538563     History of Changes
Other Study ID Numbers: Onconova 04-03
First Posted: February 24, 2012    Key Record Dates
Last Update Posted: June 23, 2017
Last Verified: June 2017

Keywords provided by Onconova Therapeutics, Inc.:
ON 01910.Na
rigosertib sodium

Additional relevant MeSH terms:
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs